Study of memapsin 2 (β-secretase) and strategy of inhibitor design

Author: Tang Jordan   Ghosh Arun   Hong Lin   Koelsch Gerald   Turner Robert   Chang Wanpin  

Publisher: Humana Press, Inc

ISSN: 0895-8696

Source: Journal of Molecular Neuroscience, Vol.20, Iss.3, 2003-08, pp. : 299-304

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The discovery that β-secretase is a membrane-anchored aspartic protease memapsin 2 has stimulated much interest in the design and testing of its inhibitors for the treatment of Alzheimer’s disease. This article discusses the strategy for the development of such inhibitor drugs. Enzymology and structural determination tools have permitted the design of memapsin 2 inhibitors with high potency and in a size range possible for penetration of the blood-brain barrier. Transgenic Alzheimer’s mice have been used to show that when memapsin 2 inhibitors are transported to the brain, they effectively reduce the production of amyloid β. Although development of a clinical candidate of memapsin 2 inhibitor drug remains a very challenging undertaking, the progress so far lends some optimism for future prospects.